Arsanis, Inc.

Arsanis, Inc. is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments.

The company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated with high mortality in spite of low rates of antibiotic resistance.

Using first-in-class monoclonal antibody discovery technologies that support the selection of highly potent antibodies with unique qualities, Arsanis, Inc. is building a broad portfolio of infectious disease targets.

Status: Active